Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemia-reperfusion injury in vivo.

Motoki A, Merkel MJ, Packwood WH, Cao Z, Liu L, Iliff J, Alkayed NJ, Van Winkle DM.

Am J Physiol Heart Circ Physiol. 2008 Nov;295(5):H2128-34. doi: 10.1152/ajpheart.00428.2008. Epub 2008 Oct 3.

2.

Soluble epoxide hydrolase: a new target for cardioprotection.

Gross GJ, Nithipatikom K.

Curr Opin Investig Drugs. 2009 Mar;10(3):253-8. Review.

3.

Soluble epoxide hydrolase inhibitors and heart failure.

Qiu H, Li N, Liu JY, Harris TR, Hammock BD, Chiamvimonvat N.

Cardiovasc Ther. 2011 Apr;29(2):99-111. doi: 10.1111/j.1755-5922.2010.00150.x. Review.

4.

Pharmacological inhibition of the soluble epoxide hydrolase-from mouse to man.

Revermann M.

Curr Opin Pharmacol. 2010 Apr;10(2):173-8. doi: 10.1016/j.coph.2009.12.002. Epub 2010 Jan 14. Review.

PMID:
20079692
5.

Soluble epoxide hydrolase inhibitors and cardiovascular diseases.

Wang ZH, Davis BB, Jiang DQ, Zhao TT, Xu DY.

Curr Vasc Pharmacol. 2013 Jan;11(1):105-11. Review.

PMID:
22303912
6.

Genetic deletion of soluble epoxide hydrolase provides cardioprotective responses following myocardial infarction in aged mice.

Jamieson KL, Samokhvalov V, Akhnokh MK, Lee K, Cho WJ, Takawale A, Wang X, Kassiri Z, Seubert JM.

Prostaglandins Other Lipid Mediat. 2017 Jan 16. pii: S1098-8823(17)30001-1. doi: 10.1016/j.prostaglandins.2017.01.001. [Epub ahead of print] Review.

PMID:
28104457
7.

Epoxyeicosatrienoic acids and cardioprotection: the road to translation.

Oni-Orisan A, Alsaleh N, Lee CR, Seubert JM.

J Mol Cell Cardiol. 2014 Sep;74:199-208. doi: 10.1016/j.yjmcc.2014.05.016. Epub 2014 Jun 2. Review.

8.

Soluble epoxide hydrolase: gene structure, expression and deletion.

Harris TR, Hammock BD.

Gene. 2013 Sep 10;526(2):61-74. doi: 10.1016/j.gene.2013.05.008. Epub 2013 May 20. Review.

9.

Role of epoxyeicosatrienoic acids in protecting the myocardium following ischemia/reperfusion injury.

Seubert JM, Zeldin DC, Nithipatikom K, Gross GJ.

Prostaglandins Other Lipid Mediat. 2007 Jan;82(1-4):50-9. Epub 2006 Jul 10. Review.

10.

Soluble epoxide hydrolase inhibition, epoxygenated fatty acids and nociception.

Wagner K, Inceoglu B, Hammock BD.

Prostaglandins Other Lipid Mediat. 2011 Nov;96(1-4):76-83. doi: 10.1016/j.prostaglandins.2011.08.001. Epub 2011 Aug 10. Review.

11.

Targeting epoxides for organ damage in hypertension.

Imig JD.

J Cardiovasc Pharmacol. 2010 Oct;56(4):329-35. doi: 10.1097/FJC.0b013e3181e96e0c. Review.

12.

Soluble epoxide hydrolase inhibition reveals novel biological functions of epoxyeicosatrienoic acids (EETs).

Inceoglu B, Schmelzer KR, Morisseau C, Jinks SL, Hammock BD.

Prostaglandins Other Lipid Mediat. 2007 Jan;82(1-4):42-9. Epub 2006 Jul 5. Review.

13.

Mechanism of the sex difference in endothelial dysfunction after stroke.

Davis CM, Fairbanks SL, Alkayed NJ.

Transl Stroke Res. 2013 Aug;4(4):381-9. doi: 10.1007/s12975-012-0227-0. Review.

14.

Soluble epoxide hydrolase in atherosclerosis.

Wang YX, Ulu A, Zhang LN, Hammock B.

Curr Atheroscler Rep. 2010 May;12(3):174-83. doi: 10.1007/s11883-010-0108-5. Review.

15.

Epoxyeicosatrienoic Acid as Therapy for Diabetic and Ischemic Cardiomyopathy.

Romashko M, Schragenheim J, Abraham NG, McClung JA.

Trends Pharmacol Sci. 2016 Nov;37(11):945-962. doi: 10.1016/j.tips.2016.08.001. Epub 2016 Sep 13. Review.

PMID:
27633970
16.

Sphingolipid therapy in myocardial ischemia-reperfusion injury.

Gundewar S, Lefer DJ.

Biochim Biophys Acta. 2008 Mar;1780(3):571-6. Epub 2007 Sep 6. Review.

Supplemental Content

Support Center